[Skip to Content]
[Skip to Content Landing]
November 1984

Schneider's First-Rank Symptoms of SchizophreniaAn Association With Increased Growth Hormone Response to Apomorphine

Author Affiliations

From the Medical Research Council Brain Metabolism Unit, Royal Edinburgh Hospital, and the Department of Pharmacology, University of Edinburgh (Drs Whalley, Christie, and Arbuthnott); and the Immunoassay Section, Department of Clinical Chemistry, University of Edinburgh (Dr Brown). Dr Brown is now with the Department of Clinical Biochemistry, Central Pathology Laboratory, Stoke-on-Trent, England.

Arch Gen Psychiatry. 1984;41(11):1040-1043. doi:10.1001/archpsyc.1983.01790220030005

• Growth hormone and prolactin (PRL) responses to 0.75 mg of apomorphine hydrochloride were measured in 19 newly admitted psychotic patients who had been untreated by neuroleptic or antidepressant drugs for at least nine months. We compared hormonal responses between subgroups of patients who were distinguished using the diagnostic criteria of Feighner et al and Spitzer et al, and by the presence or absence of Schneider's first-rank symptoms of schizophrenia. We included nine healthy subjects who were matched by age and sex with the schizophrenic patients. Growth hormone responses to apomorphine were greater in patients with Schneider's first-rank symptoms than in those without firstrank symptoms, and were also greater than in control subjects. Suppression of plasma PRL was also greater in schizophrenic patients than in control subjects. These results support the dopamine hypothesis of schizophrenia.